Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Bioprinting and Tissue Engineering

James Hickman's Biography

James Hickman, Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering, University of Central Florida; Chief Scientist, Hesperos

James J. Hickman is a founder and current Chief Scientist of Hesperos, located in Orlando, Florida, which is focusing on cell-based systems for drug discovery and toxicity. He is also the Founding Director of the NanoScience Technology Center and a Professor of Nanoscience Technology, Chemistry, Biomolecular Science, Material Science and Electrical Engineering at the University of Central Florida. Previously, he held the position of the Hunter Endowed Chair in the Bioengineering Department at Clemson University. Dr. Hickman has a Ph.D. from the Massachusetts Institute of Technology in Chemistry. For the past twenty-five years, he has been studying the interaction of biological species with modified surfaces, first in industry and in the latter years in academia. While in industry he established one of the first bioelectronics labs in the country that focused on cell-based sensors and their integration with electronic devices and MEMS devices. He is interested in creating hybrid systems for biosensor and biological computation applications and the creation of functional in vitro systems for human body-on-a-chip applications. He has worked at NSF and DARPA in the area of biological computation. He is a Fellow of both the American Institute of Medical and Biomedical Engineers (AIMBE) (2004) and the American Vacuum Society (AVS) (2007). He was a Board Member for AIMBE from 2009-2013 and Co-Chaired 6 AIMBE/NIH Workshops on “Validation and Qualification of New In Vitro Tools and Models for The Pre-clinical Drug Discovery Process” held at the NIH Campus, Bethesda, MD (2012 – 2017). Dr. Hickman along with Dr. Michael Shuler, won the Lush Prize, in the Science Category, which Supports Animal Free Testing in 2015. He has 135 publications and 20 book chapters, in addition to 22 issued patents out of 44 total patent applications.

James Hickman Image

Human-on-a-Chip Systems for Concurrent Toxicity and Efficacy Evaluation for Pre-Clinical Applications

Monday, 26 March 2018 at 15:00

Add to Calendar ▼2018-03-26 15:00:002018-03-26 16:00:00Europe/LondonHuman-on-a-Chip Systems for Concurrent Toxicity and Efficacy Evaluation for Pre-Clinical

The utilization of human-on-a-chip or body-on-a-chip systems for toxicology and efficacy that ultimately should lead to personalized medicine has been a topic that has received much attention recently. Currently drug discovery and subsequent regulatory approval for new candidates requires 10-15 years of development time before general availability is granted by either the FDA or EMA. This can be at either the single organ level, or more importantly, advanced systems where multiple organ mimics are integrated in a serum-free defined medium under flow to allow organ to organ communication and interactions for mechanistic investigations for not only safety but efficacy as well. The idea is to integrate BioMEMs devices and surface modifications with protein and cellular components, for initiating and maintaining self-assembly and growth into biologically, mechanically and electronically interactive functional multi-component systems. A functional neuromuscular junction model composed of human stem cell derived motoneurons and muscle has been used to produce dose response curves for synaptic cleft toxins. Cardiac modules have been developed that allow independent evaluation of electrical conduction and force generation in cardiac muscle for mechanistic studies for both human iPSC and embryonic stem cells. These have also been combined with liver systems in the same platform to include metabolic effects that have been demonstrated with 4 different drug/metabolic pairs. Recently a 4-organ system with recirculating medium was demonstrated for 28 days and exhibited toxicity with 5 drugs that reproduced in vivo results. Detailed results with the above system will be presented as well as results from collaboration with industry partners. There is currently a focus at the NIH, FDA and EMA to understand how one could validate these systems such that qualification could be granted for their use to augment and possibly replace animal studies. This talk will also give results of six workshops held at NIH as a collaboration between the American Institute for Medical and Biological Engineering (AIMBE) and NIH to explore what is needed for validation and qualification of these new systems.

Add to Calendar ▼2018-03-26 00:00:002018-03-27 00:00:00Europe/London3D-Bioprinting and Tissue